



H1 and Q2 2026 Results

Conference call and webcast for investors
and analysts

27 July 2026



Cautionary statements regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement:

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the risk of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet our sustainability targets, regulatory requirements or stakeholder expectations with respect to the environment; the risk of failure to meet regulatory and ethical expectations on commercial practices, including anti-bribery anti-corruption, anti-fraud and scientific exchanges; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property risks related to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business; the risk of failure in internal control, financial reporting or the occurrence of fraud; and the risk of unexpected deterioration in the Group's financial position.



H1 and Q2 2026 Results

Conference call agenda

CEO Opening Remarks	Pascal Soriot Chief Executive Officer	
Financial Results	Aradhana Sarin Chief Financial Officer	
Oncology Haematology	Dave Fredrickson EVP, Oncology Haematology Business	Susan Galbraith EVP, Oncology Haematology R&D
BioPharmaceuticals	Ruud Dobber EVP, BioPharmaceuticals Business	Sharon Barr EVP, BioPharmaceuticals R&D
Rare Disease	Marc Dunoyer Chief Executive Officer, Alexion	
CEO Closing Remarks, Q&A	Pascal Soriot Chief Executive Officer	





CEO Opening Remarks

Pascal Soriot
CHIEF EXECUTIVE OFFICER





Commercial performance and pipeline delivery in H1 2026 drive confidence in \$80bn Total Revenue ambition

SUSTAINED COMMERCIAL MOMENTUM	+6%	Total Revenue
	+11%	Total Revenue, ex. <i>Farxiga</i> and <i>Brilinta</i> ¹
	+11%	Core EPS
MEANINGFUL PROGRESS FOR OUR PIPELINE ²	6	positive key Phase III programme readouts
	1st Phase III data for 3 NMEs	sonesitatug vedotin tozorakimab efzimfotase alfa
	1st approval for 2 NMEs	ETCAMAH™ camizestrant BAXFENDY™ baxdrostat


5 All growth rates at CER compared to H1 2025. 1. Revenue growth calculated excluding *Farxiga* and *Brilinta* following LOEs in certain major markets. 2. Since FY 2025 results.
Appendix: [Glossary](#).




Growth driven by diverse sources of business and global presence



Strength across therapy areas
H1 2026 | +6% Product Revenue (\$m)¹



Growth across geographies
H1 2026 | + 6% Product Revenue (\$m)¹



Continued pipeline momentum in H1 2026

KEY POSITIVE PHASE III PROGRAMME READOUTS

EMERALD-3 <i>Imfinzi + Imjudo</i> liver cancer	VOLGA <i>Imfinzi ± Imjudo</i> bladder cancer	CLARITY-Gastric01 <i>sonesitug vedotin</i> gastric cancer NME	OBERON / TITANIA / MIRANDA <i>tozorakimab</i> COPD NME	HICKORY / CHESTNUT / MULBERRY <i>efzimfotase alfa</i> hypophosphatasia NME	I CAN <i>Ultomiris</i> IgAN
---	---	--	---	---	--

FIRST MAJOR MARKET APPROVALS FOR NEW INDICATIONS

BREAST CANCER	Enhertu DESTINY-Breast05	Datroway TROPION-Breast02	GU CANCERS	Imfinzi POTOMAC	HYPER-TENSION	Baxfendy BaxHTN NME
	Enhertu DESTINY-Breast11	Etcamah SERENA-6 NME		Truqap CAPitello-281	ASTHMA	Breztri KALOS/LOGOS





Financial Results

Aradhana Sarin

CHIEF FINANCIAL OFFICER



H1 and Q2 2026 – Reported profit and loss

	H1 2026 \$m	CER change %	% Total Revenue	Q2 2026 \$m	CER change %	% Total Revenue
- Product Sales	28,896	5	94	14,510	4	94
- Alliance Revenue	1,699	29	6	874	33	6
Product Revenue	30,595	6	100	15,384	5	100
- Collaboration Revenue	77	(9)	-	-	n/m	-
Total Revenue	30,672	6	100	15,384	5	100
<i>Gross Margin</i>	83%	-		84%	-	
- R&D expense	(7,545)	10	25	(4,053)	13	26
- SG&A expense	(10,571)	10	34	(5,651)	14	37
Total operating expense ¹	(18,402)	10	60	(9,849)	14	64
Other operating income and expense	341	76	1	152	93	1
Operating profit	7,410	2	24	3,164	(13)	21
Tax rate	17%			10%		
Reported EPS	\$3.60	3		\$1.61	(2)	

⁹ Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.

1. Total operating expense includes distribution, R&D and SG&A expenses.

Appendix: [Glossary](#).



H1 and Q2 2026 – Core profit and loss

	H1 2026 \$m	CER change %	% Total Revenue	Q2 2026 \$m	CER change %	% Total Revenue
- Product Sales	28,896	5	94	14,510	4	94
- Alliance Revenue	1,699	29	6	874	33	6
Product Revenue	30,595	6	100	15,384	5	100
- Collaboration Revenue	77	(9)	-	-	n/m	-
Total Revenue	30,672	6	100	15,384	5	100
<i>Gross Margin</i>	83%	+1pp		84%	+1pp	
- R&D expense	(7,123)	6	23	(3,662)	5	24
- SG&A expense	(7,909)	6	26	(4,050)	4	26
Total operating expense ¹	(15,318)	6	50	(7,857)	4	51
Other operating income and expense	341	81	1	152	>2x	1
Operating profit	10,510	11	34	5,158	10	34
Tax rate	18%			15%		
Core EPS	\$5.21	11		\$2.63	18	

¹⁰ Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.

1. Total operating expense includes distribution, R&D and SG&A expenses.


Appendix: [Glossary](#).



FY 2026 guidance reiterated

Capital allocation priorities remain unchanged

Net debt/EBITDA 1.3x



FY 2026 Guidance (CER)

Total Revenue	Anticipated to increase by a mid-to-high single-digit percentage
Core EPS	Anticipated to increase by a low double-digit percentage

- Core tax rate expected to be between 18-22%
- Anticipated FX impact⁵: low single-digit positive impact on Total Revenue and neutral on Core EPS

11 Due to rounding, the sum of the dollar values and percentages may not agree to totals. 1. Capital expenditure on tangible assets and software-related intangible assets. 2. Comprises purchase and disposal of intangible assets (excluding software-related assets, including AZ Forest), purchase and disposal of non-current asset investments, payments to associates and joint ventures, payments to acquire non-controlling interests, disposal of investments in associates and joint ventures, acquisitions of subsidiaries, net of acquired net debt and payment of contingent consideration on business combinations. The Company mainly uses debt issuance or available cash to finance new Business Development opportunities. 3. Comprises mainly shares purchased by Employee Benefit Trust and recognition of Kendall Square lease liability. 4. Rolling 12-month EBITDA. AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A1, outlook positive. S&P Global Ratings: short-term rating A-1, long-term rating A+, outlook stable. 5. If foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026. Appendix: [Glossary](#).





Oncology

Dave Fredrickson

ONCOLOGY HAEMATOLOGY BUSINESS


Susan Galbraith

ONCOLOGY HAEMATOLOGY R&D



Oncology – H1 and Q2 2026

Total Revenue +15% in Q2 and H1 2026 driven by robust global demand across key medicines



Tagrisso Imfinzi + Imjudo Calquence Enhertu Truqap Lynparza (PR) Others¹ Lynparza (CR)

Q2 2026: key dynamics

- **Tagrisso** +6%, extending 1L leadership with accelerating FLAURA2 uptake in growing combo market
- **Imfinzi** +27%, **Imjudo** (7%), robust global demand growth driven by new launches
- **Calquence** +16%, continued BTKi leadership in 1L CLL across major markets
- **Enhertu** +31%, strong global demand growth, driven by breast indications
- **Truqap** +37%, continued ex-US growth, 2L US share stable
- **Datroway** \$55m, share in 2L EGFRm lung increasing, leading position in 3L+

Key regulatory approvals:

- US (*Datroway* TROPION-Breast02, *Enhertu* DESTINY-Breast05 & -11, *Imfinzi* POTOMAC, *Truqap* CAPItello-281)
- EU (*Enhertu* DESTINY-PanTumor02², *Etcamah* SERENA-6)
- JP (*Calquence* AMPLIFY, *Etcamah* SERENA-6, *Imfinzi* MATTERHORN)



Oncology – leadership in *EGFR*m lung cancer

Commercial, BD and pipeline strength consolidate our position across *EGFR*m NSCLC

Continued strong growth with *Tagrisso* globally

#1 3rd gen EGFR TKI
prescribed globally¹

>75% FLAURA2 share of
1L US combination
market²

Zegfrovy broadens reach across *EGFR*m disease³

Already approved in 2L in US, launched in China

1L filings submitted based on global Phase III WU-KONG28 trial⁴

Pipeline ensures continued leadership

Establishing novel combinations in 2L+

**TROPION-
Lung15**

Datroway ± Tagrisso

H2 2026

SAFFRON

Tagrisso + Orpathys

H2 2026

Expanding 1L disease leadership

**TROPION-
Lung14**

Datroway + Tagrisso

>2027

1. IQVIA MIDAS monthly data by May 2026. 2. IQVIA US May 2026 ATU data. 3. *Zegfrovy* is approved in the US and China for the treatment of adult patients with locally advanced or metastatic NSCLC with *EGFR* exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. 4. A Supplemental New Drug Application for approval in the 1st-line setting has been submitted to the US FDA and China's CDE.

AstraZeneca has entered into an exclusive license agreement with Dical Pharmaceutical Co., Ltd for *Zegfrovy* (sunvozertinib). AstraZeneca will acquire worldwide rights to develop and commercialise *Zegfrovy*. The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances. Collaboration partners: Daiichi Sankyo (*Datroway*), Hutchmed (*Orpathys*).

Appendix: [Glossary](#).



Oncology – Phase III data readouts transforming practice

Data readouts reinforce AstraZeneca potential in areas of high unmet need

VOLGA | *Imfinzi* + EV +/- *Imjudo* reframing outcomes with cisplatin-ineligible MIBC

Imfinzi + EV

Met primary endpoint: Clinically meaningful improvements in EFS and OS

Imfinzi + EV + *Imjudo*

Clinically meaningful EFS improvement, OS trend

Imfinzi data across bladder cancer spectrum

High-risk NMIBC	MIBC	1L mUC
POTOMAC 	cis-eligible NIAGARA  cis-ineligible VOLGA 	NILE 

CLARITY-Gastric01 | *sonve* transforming outcomes in 2L+ Claudin 18.2+ gastric cancer

Met primary endpoint: Highly clinically meaningful OS improvement in patients treated with ≥ 2 prior therapies¹

Met key secondary endpoint: Highly clinically meaningful OS benefit in patients treated with ≥ 1 prior therapy

>180k

patients with 2L+ Claudin 18.2+ gastric cancer²

20%

patients alive 1 year after diagnosis with advanced gastric cancer

First global Phase III to show **survival benefit** with Claudin 18.2 ADC in 2L+ gastric cancer setting





BioPharmaceuticals

Ruud Dobber

BIOPHARMACEUTICALS BUSINESS



Sharon Barr

BIOPHARMACEUTICALS R&D



BioPharmaceuticals – H1 and Q2 2026

Total Revenue -5% to \$11.2bn; CVRM LoE impact largely offset by growth in R&I



Q2 2026: key dynamics

- **Fasenra** +13%, sustained IL-5 leadership in asthma, EGPA growth, ongoing China launch
- **Breztri** +20%, fastest growing medicine in expanding FDC triple class in COPD
- **Tezspire** +45%, sustained demand growth in severe asthma supported by nasal polyps launch
- **Saphnelo** +24%, increasing penetration of i.v. formulation; subcutaneous launch in US and EU
- **Farxiga** (19%), generic competition in US and Japan; VBP in China; growth in other regions
- **Wainua** +58%, demand growth in ATTR-PN

Key regulatory approvals:

- US, EU, JP, CN (**Fasenra** NATRON)
- EU CHMP (**Breztri** KALOS / LOGOS)



BioPharmaceuticals – key pipeline developments in Q2 2026

Wainua | CARDIO-TTRansform Phase III trial

ATTR-CM trial in contemporary patient population

Primary endpoint not met; *Wainua* monotherapy showed nominal statistically significant benefit

Data to be presented at ESC congress in August

Additional catalysts | Advancing late-stage assets

SARA (AZD6234)
Phase III trial initiating

laroprovstat + rosuvastatin
Phase III trial initiating

Positive Phase III data for **tozorakimab** at ERS

elecoglipron | Phase IIb VISTA and SOLSTICE at ADA



Clinically meaningful efficacy
11.8% weight loss¹ and 1.9% HbA1c reduction²



Favourable safety
GI tolerability and safety consistent with GLP-1 RA class



Convenient small molecule
No food or fluid restrictions; combinable oral small molecule

Initiating a broad Phase III programme:

EMBOLD	ELUMINATE	ELEVATE
- Obesity or overweight (± T2D) - elecoglipron monotherapy	- T2D - elecoglipron ± dapagliflozin	- Outcomes trials on background dapa + other SOC - HFpEF trial - CKD (± T2D) trial
FSI	FSI	





Rare Disease


Marc Dunoyer

CHIEF EXECUTIVE OFFICER, ALEXION



Rare Disease – H1 and Q2 2026

Total Revenue \$4.9bn in H1 driven by continued patient demand across the portfolio



Q2 2026: key dynamics

C5 Franchise

- **Ultomiris** +12%, growth across indications, including within the competitive gMG and PNH markets
- **Soliris** (28%), successful conversion to *Ultomiris* and additional impact from biosimilars in US and EU

Beyond Complement

- **Strengiq** +36%, strong global demand from patients with HPP
- **Koselugo** +27%, continued growth, including newly launched adult indication



Rare Disease – Phase III presentations at congresses across rare disease indications

Ultomiris | Expanding further into nephrology with I CAN Phase III trial

43%

reduction in proteinuria in IgAN patients¹

Significant proteinuria reduction, seen as early as 10 weeks

Well positioned in an increasingly competitive IgAN market

Filed in US and JP

efzimfotase alfa | Transformative data for paediatric HPP with MULBERRY and CHESTNUT

Clinically meaningful improvement in bone health

Significant improvement in function and QoL measures

361

days per year free from ISRs^{2,3}

**Filing in major markets
for broad HPP population**

21
1. Barratt J, et al Ravulizumab in IgA nephropathy: a prespecified interim analysis of a randomized phase 3 trial (I CAN). Presented at European Renal Association (ERA) Congress; 2026 Jun 6; Glasgow, Scotland. 2. Simmons JH, et al Efficacy and Safety of Alkaline Phosphatase (ALP) Enzyme Replacement Therapy (ERT) Efzimfotase Alfa in Children with Hypophosphatasia (HPP): Results of MULBERRY and CHESTNUT as Part of a Three-trial Phase 3 Clinical Program. Presented at ICCBH congress; 2026 Jun 28, Montreal, Canada. 3. The median number of ISR-free days is based on estimates of annualised patient-level ISR days. ISR = injection site reaction
Appendix: [Glossary](#).





CEO Closing Remarks

Pascal Soriot
CHIEF EXECUTIVE OFFICER



Continuing pipeline momentum with key Phase III readouts

H1 2026

EMERALD-3 | *Imfinzi + Imjudo* 
locoregional HCC

VOLGA | *Imfinzi ± Imjudo* 
muscle-invasive bladder cancer

OBERON/TITANIA/MIRANDA | 
tozorakimab COPD

I CAN | *Ultomiris* 
IgAN

ARTEMIS | *Ultomiris* 
CSA-AKI

HICKORY/CHESTNUT/MULBERRY | 
efzimfotase alfa hypophosphatasia

H2 2026

AVANZAR | *Datroway + Imfinzi*
1L NSQ/NSQ TROP2+ NSCLC

TROPION-Lung15 | *Datroway ± Tagrisso* 2L EGFRm NSCLC

SERENA-4 | *Etcamah*
1L HR+ HER2- adv. breast cancer

PACIFIC-9 | *Imfinzi + oleclumab/monalizumab* unresect. stg. III NSCLC

SAFFRON | *Tagrisso + Orpathys*
2L EGFRm NSCLC

CLARITY-Gastric01 | *sonesitug vedotin* 2L+ CLDN18.2+ gastric cancer 

CARDIO-TTRansform | *Wainua* 
ATTR-CM

CROSSING | *Tezspire*
eosinophilic esophagitis

TMA-313 | *Ultomiris* 
HSCT-TMA (adults)

H1 2027

TROPION-Lung07 | *Datroway*
1L NSQ/NSQ TROP2+ NSCLC

eVOLVE-Lung02 | *volrustomig*
1L mNSCLC

DAISY | *Saphnelo*
systemic sclerosis

IRIS | *Saphnelo*
lupus nephritis

LAVENDER | *Saphnelo*
cutaneous lupus erythematosus

BalanceD-HF | *balcinrenone + dapagliflozin* HF with renal impairment

AZURE-LDL/AZURE-HeFH |
laroprovstat dyslipidemia

ZENITH High Proteinuria | *zibotentan + dapagliflozin* CKD with high proteinuria

H2 2027

TROPION-Breast03 | *Datroway + Imfinzi* post-neoadjuvant TNBC

TROPION-Breast05 | *Datroway + Imfinzi* 1L PD-L1 CPS ≥10 TNBC

CAMBRIA-1 | *Etcamah*
adj. switch HR+ HER2- early breast cancer

PACIFIC-4 | *Imfinzi*
unresect. stg. I/II NSCLC

CAPitello-292 | *Truqap*
1L early relapse/ET resistant HR+ adv. BC

Bluestar-Endometrial01 | *puxi-sam*
2-3L B7-H4+ endometrial cancer

EvoPAR-Prostate01 | *saruparib*
1L mCSPC

eVOLVE-Cervical | *volrustomig*
high-risk locally advanced cervical cancer

BaxPA | *Baxfendy*
primary aldosteronism

JASMINE | *Saphnelo*
idiopathic inflammatory myopathies

TILIA | *tozorakimab*
lower respiratory tract disease



Strategically investing to deliver growth beyond 2030

Significant progress across our transformative technologies in H1 2026

Weight management and CV risk factors

First Phase III data for **laroprovstat** H1 2027

6 Phase III trials initiated for **elecoglipron**

AZD6234 Phase II readout H1 2026
AZD6234/AZD9550 Phase IIb expected H2 2026

ADCs and radio-conjugates

First positive Phase III data: **sone-ve** in CLARITY-Gastric01

First Phase III data for **puxi-sam** H2 2027 in Bluestar-Endometrial01

First patients dosed in **torvu-sam** and **zada-gu** Phase III programmes in Q2 2026

Next-gen IO bispecifics

16 Phase III trials across **9 tumour** types

5 Phase III trials in combination with ADCs

Subcutaneous rilvegostomig development ongoing

Cell therapy & T-cell engagers


Ongoing Phase III for **AZD0120** in r/r multiple myeloma; further Phase III initiating in newly diagnosed disease

Ongoing **surovatamig** Phase IIIs in follicular lymphoma and DLBCL

AZD0120 and **surovatamig** ongoing early trials in autoimmune disease



NMEs with pivotal data readouts before 2030 drive growth into the next decade



Deep late-stage pipeline of **multi-blockbuster opportunities**

Increasing confidence in Ambition 2030 and continued growth beyond



Continued commercial momentum in 2026

Strong global demand across medicines



Advancing towards \$80bn 2030 Total Revenue ambition¹

Significant pipeline progress increases confidence



Investment in growth beyond 2030

Strategic focus to fuel growth into next decade



Q&A Session



Pascal Soriot
CHIEF EXECUTIVE OFFICER



Aradhana Sarin
CHIEF FINANCIAL OFFICER



Marc Dunoyer
CHIEF EXECUTIVE OFFICER,
ALEXION



Susan Galbraith
EVP, ONCOLOGY
HAEMATOLOGY R&D



Dave Fredrickson
EVP, ONCOLOGY
HAEMATOLOGY BUSINESS



Sharon Barr
EVP, BIOPHARMACEUTICALS
R&D



Ruud Dobber
EVP, BIOPHARMACEUTICALS
BUSINESS



Iskra Reic
EVP, INTERNATIONAL





Appendix



AstraZeneca P&L reference table

P&L line-item definitions

	P&L line-item definition
Product Sales	- Recognises sales from territories where Group has lead commercialisation - Recognises supply of <i>Beyfortus</i> to Sanofi
Alliance Revenue	Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration partners, where AstraZeneca is entitled to a share of gross profits, share of revenues or royalties, which are recurring in nature while the collaboration agreement remains in place¹
Product Revenue	The sum of Product Sales and Alliance Revenue
Collaboration Revenue	Recognises any development or sales-based milestone received on partnered medicines as well as any upfront payments associated with business development where AstraZeneca retains a significant ongoing economic interest in the product
Total Revenue	Sum of Product Sales, Alliance Revenue and Collaboration Revenue
Gross Margin	Calculated by dividing Gross Profit by Total Revenue
Other operating income & expense	Other operating income and expense is generated from activities outside of the Group's normal course of business, which includes Other income from divestments of or full out-license of assets and businesses including royalties and milestones where the Group does not retain a significant continued interest
Core² Operating margin	Defined as Core Operating profit as a percentage of Total Revenue



AstraZeneca P&L

2026 P&L modelling considerations

P&L line	P&L
Total Revenue	Expected to grow by a mid-to-high single digit percentage at CER (guidance)
Gross margin	Core gross margin expected to be stable to slightly better vs. 2025
R&D	Core R&D expenses expected to be at the upper end of the low 20%s range (of Total Revenue)
Other operating income	Similar level of OOI anticipated in 2H as in 1H 2026
Finance expenses	Core Finance expenses anticipated to be higher vs. 2025
Tax	Core tax rate expected to be between 18-22% for the full year
Core EPS	Expected to grow by a low double-digit percentage at CER (guidance)
FX-impact	If foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026, a low single-digit positive impact is anticipated on Total Revenue and a neutral impact on Core EPS



AstraZeneca in non-small cell lung cancer

	Resectable		Unresectable			Metastatic	
	Stg. I	Stg. II-III	Stg. I-II	Stg. III	1L	2L	3L+
Est. epi (G7, 2025)	~150K	~70K	~50K	~100K	~310K	~190K	~70K
IO sensitive ~70%	Imfinzi AEGEAN		SBRT → Imfinzi / Tagrisso PACIFIC-4	CRT → Imfinzi PACIFIC	Imfinzi + Imjudo + CTx POSEIDON	Datroway TROPION-Lung17 NSQ TROP2-NMR+	
				Imfinzi combos PACIFIC-9 improvements across PD-L1 spectrum	Datroway + IO ± platinum TL08/TL07/AVANZAR		
					rilvegostomig ± Datroway TROPION-Lung10		
					rilvegostomig + CTx PDL1≥1% SQ ARTEMIDE-Lung02		
					rilvegostomig + CTx PDL1≥1% NSQ ARTEMIDE-Lung03		
					rilvegostomig PDL1≥50% ARTEMIDE-Lung04		
					volrustomig + CTx eVOLVE-Lung02		
Enhertu + pembrolizumab HER2+ PDL1<50% DESTINY-Lung06							
EGFRm ~16-19%	Tagrisso ADAURA2	Tagrisso ADAURA	CRT → Tagrisso LAURA	Tagrisso FLAURA	Tagrisso + Orpathys SAFFRON/SAVANNAH	Datroway TROPION-Lung05	
		Tagrisso neoADAURA		Tagrisso + CTx FLAURA-2			Datroway ± Tagrisso TROPION-Lung15
	Datroway + Tagrisso TROPION-Lung14						
Other tumour drivers ~12%				CRT → Imfinzi PACIFIC			
HER2m ~2%					Enhertu DESTINY-Lung04	Enhertu DESTINY-Lung02	

Key:

DXd ADC

IO

TKI

IO bispecific

launched and
established SoClaunched
indication

AstraZeneca in breast cancer

	Early			Metastatic			
	Neoadjuvant	Adjuvant		1st line	2nd line	3rd line	4th line +
Est. epi (G7, 2025)	540k			135k	100k	75k	60k
HER2-positive 15-20%	 <i>Enhertu</i> → THP DESTINY-Breast11	 NST→ residual disease → <i>Enhertu</i> DESTINY-Breast05		 <i>Enhertu</i> ± pertuzumab DESTINY-Breast09	 <i>Enhertu</i> DESTINY-Breast03	 <i>Enhertu</i> DESTINY-Breast01/02	
HR-positive 65-75%		Good outcomes with current SoC for low-risk patients CTx → camizestrant ± abemaciclib CAMBRIA-2 CTx → AI ± CDK4/6i 2-5 yrs → camizestrant CAMBRIA-1	RECURRENCE	camizestrant + palbociclib SERENA-4  AI + CDK4/6i → camizestrant + CDK4/6i SERENA-6 <i>ESR1m 35%</i> <i>Truqap</i> + <i>Faslodex</i> + CDK4/6i CAPitello292 saruparib + camizestrant EvoPAR-Breast01 <i>tBRCAm, PALB2m 9%</i>	<i>Truqap</i> + <i>Faslodex</i> CAPitello291 <i>PIK3CA, AKT1, PTEN alt. 40%</i>  <i>Enhertu</i> DESTINY-Breast06 HER2-low (1+, 2+) 60% HER2-ultralow (0-1+) 25% DESTINY-Breast04 HER2-low (1+, 2+) 35%	<i>Datroway</i> TROPION-Breast01 <i>Enhertu</i> DESTINY-Breast04 HER2-low (1+, 2+) 60%	
TNBC 10-15%	<i>Datroway</i> + <i>Imfinzi</i> TROPION-Breast04	NST → residual disease → <i>Datroway</i> ± <i>Imfinzi</i> TROPION-Breast03		<i>Datroway</i> + <i>Imfinzi</i> TROPION-Breast05 PD-L1-elig. 30%  <i>Datroway</i> TROPION-Breast02 PD-L1-inelig. 70%	DESTINY-Breast04 HER2-low (1+, 2+) 35%	HER2-low (1+, 2+) 35%	
gBRCAm 5% of HR-positive 15% of TNBC		 CTx → <i>Lynparza</i> OlympiA			<i>Lynparza</i> OlympiAD		

Key:

DXd ADC

IO

ngSERD

AKTi

PARPi

 launched and established SoC
  launched indication


AstraZeneca in gastric cancer

	Early Stage II/III		Advanced/Metastatic		
			1st line	2nd line	3rd line
Est. epi (G7, 2025)	50k		90k	60k	30k
HER2-positive 20%	Imfinzi + perioperative FLOT in resectable disease MATTERHORN	RECURRENCE	Enhertu + rilvegostomig + FP ARTEMIDE-Gastric01	Enhertu DESTINY-Gastric02, 04	Enhertu DESTINY-Gastric01
			Enhertu + pembrolizumab + FP DESTINY-Gastric05		
Claudin18.2- positive 45-50%			sonesitug vedotin + CTx ± rilvegostomig CLARITY-Gastric02	sonesitug vedotin CLARITY-Gastric01	
Other 20-25%					

Key:

DXd ADC


IO

AZ ADC

IO bispecific

launched and
established SoC launched
indication

AstraZeneca in bladder cancer



Key:

DXd ADC

IO

AZ ADC


IO bispecific

launched and
established SoClaunched
indication

Oncology


Tagrisso

6% growth at CER to \$3,775m in H1 2026



Lynparza


1% decrease at CER to \$1,610m in H1 2026



Oncology


Imfinzi

29% growth at CER to \$3,548m in H1 2026



Imjudo


7% decrease at CER to \$160m in H1 2026



Oncology


Calquence

16% growth at CER to \$1,944m in H1 2026



Enhertu


32% growth at CER to \$1,719m in H1 2026



BioPharmaceuticals: Respiratory & Immunology


Fasenra

12% growth at CER to \$1,053m in H1 2026




Tezspire

40% growth at CER to \$694m in H1 2026



Saphnelo


24% growth at CER to \$380m in H1 2026



BioPharmaceuticals: Respiratory & Immunology


Breztri

17% growth at CER to \$699m in H1 2026



Symbicort


4% decrease at CER to \$1,418m in H1 2026



BioPharmaceuticals: Cardiovascular, Renal & Metabolism


Farxiga

11% decrease at CER to \$3,998m in H1 2026




Brilinta

66% decrease at CER to \$186m in H1 2026



Lokelma


26% growth at CER to \$419m in H1 2026



Rare Disease


Ultomiris

14% growth at CER to \$2,584m in H1 2026




Strensiq

40% growth at CER to \$1,053m in H1 2026



Koselugo

21% growth at CER to \$347m in H1 2026



Glossary

1L, 2L, 3L	first-, second-, third-line
ADA	American Diabetes Association
ADC	antibody-drug conjugate
adv.	advanced
AI	aromatase inhibitor
AKT1	AKT serine/threonine kinase 1
AKTi	AKT inhibitor
ATTR-CM	transthyretin amyloid cardiomyopathy
ATTR-PN	transthyretin amyloid polyneuropathy
AZ	AstraZeneca
BCG	Bacillus Calmette-Guérin
BTk	Bruton's tyrosine kinase
C5	complement component 5
CapEx	capital expenditure
CDK4/6i	cydin-dependent kinase 4/6 inhibitor
CER	constant exchange rates
CFO	net cash inflow from operating activities
CHMP	Committee for Medicinal Products for Human Use
CKD	chronic kidney disease
CLDN18.2	Claudin-18.2
CLL	chronic lymphocytic leukaemia
CN	China
COPD	chronic obstructive pulmonary disease
CPS	combined positive score
CR	Collaboration Revenue
CRT	chemoradiotherapy
CSA-AKI	cardiac surgery-associated acute kidney injury
CTx	chemotherapy
CV	cardiovascular
CVRM	Cardiovascular, Renal and Metabolism
DLBCL	Diffuse Large B-Cell Lymphoma
Dxd	deruxtecan
EBITDA	Reported Profit before tax after adding back net finance expense, results from joint ventures and associates, and charges for depreciation, amortisation and impairment
EFS	event-free survival
EGFRm	epidermal growth factor receptor-mutant
EGPA	eosinophilic granulomatosis with polyangiitis
EM	Emerging Markets
epi	epidemiology
EPS	earnings per share
ERoW	Established Rest of World

ERS	European Respiratory Society
ESC	European Society of Cardiology
ESR1m	estrogen receptor alpha-mutated
EU	Europe
EV	enfortumab vedotin
FDC	fixed-dose combination
FLOT	fluorouracil, leucovorin, oxaliplatin and docetaxel
FP	fluoropyrimidine
FSI	first subject in
FX	foreign exchange
FY	Fiscal Year
G7	US, Japan, EU5
gBRCAm	germline BRCA-mutated breast cancer
GI	gastrointestinal
GLP-1	glucagon-like peptide-1
gMG	generalised myasthenia gravis
GU	genitourinary
HbA1c	hemoglobin A1c
HCC	hepatocellular carcinoma
HER2-/negative	human epidermal growth factor receptor 2-negative
HER2-low	human epidermal growth factor receptor 2-low
HER2-ultralow	human epidermal growth factor receptor 2-ultralow
HER2+/positive	human epidermal growth factor receptor 2-positive
HER2m	human epidermal growth factor receptor 2-mutant
HF	heart failure
HFpEF	heart failure with preserved ejection fraction
HPP	hypophosphatasia
HR+/positive	hormone receptor-positive
HSCT-TMA	hematopoietic stem cell transplantation-associated thrombotic microangiopathy
i.v.	intravenous
ID	Infectious Diseases
IgAN	immunoglobulin A nephropathy
IL-5	interleukin-5
IO	immuno-oncology
ISR	injection site reaction
JP	Japan
LOE	loss of exclusivity
M&A	mergers and acquisitions
mCSPC	metastatic castration-sensitive prostate cancer
MIBC	muscle invasive bladder cancer
mUC	metastatic urothelial carcinoma
ngSERD	next-generation selective estrogen receptor degrader

NME	new molecular entity
NMIBC	non-muscle invasive bladder cancer
NMR+	normalised membrane ratio positive
NSCLC	non-small cell lung cancer
NSQ	non-squamous
NST	neoadjuvant systemic therapy
OS	overall survival
PALB2m	partner and localizer of BRCA2
PARPi	poly-ADP ribose polymerase inhibitor
PD-L1	programmed cell death ligand 1
PFS	progression free survival
PIK3CA	phosphatidylinositol 3-kinase catalytic subunit alpha
P&L	profit and loss
PNH	paroxysmal nocturnal haemoglobinuria
pp	percentage point
PR	Product Revenue
PS	Product Sales
PTEN	phosphatase and TENsin homolog deleted on chromosome 10
PYR	Peak-Year Revenue
QoL	quality of life
RA	receptor agonist
r/r	refractory / recurrent
R&D	Research & Development
R&I	Respiratory & Immunology
SBRT	stereotactic body radiotherapy
SC	subcutaneous
SERD	selective estrogen receptor degraders
SG&A	Selling, General & Administrative
SoC	standard-of-care
SQ	squamous
Stg.	stage
T2D	type 2 diabetes
tBRCAm	tumor BRCA mutation
THP	docetaxel, trastuzumab and pertuzumab
TKI	tyrosine kinase inhibitor
TL07	TROPION-Lung07
TL08	TROPION-Lung08
TNBC	triple negative breast cancer
TROP2	trophoblast cell surface antigen 2
TSLP	thymic stromal lymphopoietin
US	United States
VBP	volume-based procurement



Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful.

AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK
+44(0)203 749 5000
www.astrazeneca.com

